- Home
- PEV vs AIM Comparison
PEV vs AIM Comparison
Compare PEV & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEV
- AIM
- Stock Information
- Founded
- PEV 2002
- AIM 1966
- Country
- PEV United States
- AIM United States
- Employees
- PEV N/A
- AIM N/A
- Industry
- PEV Auto Manufacturing
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PEV Consumer Discretionary
- AIM Health Care
- Exchange
- PEV Nasdaq
- AIM Nasdaq
- Market Cap
- PEV 10.9M
- AIM 8.8M
- IPO Year
- PEV 2022
- AIM N/A
- Fundamental
- Price
- PEV $0.30
- AIM $0.12
- Analyst Decision
- PEV
- AIM Strong Buy
- Analyst Count
- PEV 0
- AIM 2
- Target Price
- PEV N/A
- AIM $2.75
- AVG Volume (30 Days)
- PEV 6.5M
- AIM 410.1K
- Earning Date
- PEV 05-22-2025
- AIM 03-27-2025
- Dividend Yield
- PEV N/A
- AIM N/A
- EPS Growth
- PEV N/A
- AIM N/A
- EPS
- PEV 0.06
- AIM N/A
- Revenue
- PEV $26,119,000.00
- AIM $170,000.00
- Revenue This Year
- PEV N/A
- AIM N/A
- Revenue Next Year
- PEV N/A
- AIM $1,693.10
- P/E Ratio
- PEV $5.97
- AIM N/A
- Revenue Growth
- PEV 424.69
- AIM N/A
- 52 Week Low
- PEV $0.20
- AIM $0.11
- 52 Week High
- PEV $1.39
- AIM $0.62
- Technical
- Relative Strength Index (RSI)
- PEV 37.05
- AIM 40.32
- Support Level
- PEV $0.34
- AIM $0.11
- Resistance Level
- PEV $0.85
- AIM $0.16
- Average True Range (ATR)
- PEV 0.10
- AIM 0.01
- MACD
- PEV -0.04
- AIM 0.00
- Stochastic Oscillator
- PEV 0.71
- AIM 25.67
About PEV Phoenix Motor Inc.
Phoenix Motor Inc is an electrification solutions provider for the commercial vehicle industry as well as other industries. It designs, develops, manufactures, assembles, and integrates electric drive systems and light and medium-duty electric vehicles (EVs) and markets and sells electric vehicle chargers for the commercial and residential markets. The company operates two primary brands, Phoenix Motorcars, which focuses on commercial products including medium-duty electric vehicles, chargers, and electric forklifts, and EdisonFuture which intends to offer light-duty electric vehicles.
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.